Sanofi SA (EPA:SAN) PT Set at €96.00 by Deutsche Bank AG

Sanofi SA (EPA:SAN) has been assigned a €96.00 ($112.94) price target by analysts at Deutsche Bank AG in a report issued on Tuesday, August 1st. The brokerage presently has a “buy” rating on the stock.

Several other research analysts have also weighed in on SAN. HSBC Holdings plc set a €77.00 ($90.59) price objective on shares of Sanofi SA and gave the stock a “sell” rating in a research note on Friday, April 7th. J P Morgan Chase & Co set a €87.00 ($102.35) price objective on shares of Sanofi SA and gave the stock a “neutral” rating in a research note on Tuesday, April 11th. Kepler Capital Markets set a €92.00 ($108.24) price objective on shares of Sanofi SA and gave the stock a “buy” rating in a research note on Wednesday, April 12th. Morgan Stanley set a €91.00 ($107.06) price objective on shares of Sanofi SA and gave the stock a “buy” rating in a research note on Monday, April 24th. Finally, Berenberg Bank set a €92.00 ($108.24) price objective on shares of Sanofi SA and gave the stock a “buy” rating in a research note on Friday, April 28th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of €87.63 ($103.09).

Shares of Sanofi SA (EPA:SAN) opened at 82.26 on Tuesday. The firm’s 50-day moving average is €25.48 and its 200-day moving average is €25.74. Sanofi SA has a 12-month low of €62.50 and a 12-month high of €92.97. The company has a market capitalization of €103.30 billion and a PE ratio of 11.48.

TRADEMARK VIOLATION NOTICE: This news story was reported by BNB Daily and is the property of of BNB Daily. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.baseball-news-blog.com/2017/08/19/deutsche-bank-ag-analysts-give-sanofi-sa-epasan-a-96-00-price-target-updated-updated.html.

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply